An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

BACKGROUND: Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. METHODS: We assessed the relative risk for all treatment-related adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hye Duck, Kim, Ji Hae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834631/
https://www.ncbi.nlm.nih.gov/pubmed/36704607
http://dx.doi.org/10.1155/2023/7362551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834631/
https://www.ncbi.nlm.nih.gov/pubmed/36704607
http://dx.doi.org/10.1155/2023/7362551

Ejemplares similares